Covaxin vaccine ... effectively handles delta strains .... US National Institutes of Health, information ..!

The Covaxin vaccine, developed by Bharat Biotech in association with the Medical Research Council of India, effectively handles the alpha and delta strains of the corona virus, according to the US National Institutes of Health.

The NIH said the results of two studies conducted on the blood of covaxin injectors showed that the vaccine produces antibodies.

Kovacsin effectively handles the B.1.1.7 (alpha) and B.1.617 (delta) variants of SARS-CoV-2. These types of viruses have been identified in the UK and India, respectively. So we carried out this study, according to the National Institutes of Health.

It is noteworthy that two and a half crore people in India have been vaccinated against covax.

Covaxin stimulates the immune system to produce antibodies against the virus. The NIH reports that the results of the second phase of the vaccine study are safe and have fewer side effects. It is noteworthy that Kovacs' Phase 3 study data will be available later this year.

The reason why 3rd data has not yet been made public is that multinational organizations such as the World Health Organization have not approved the vaccine for covax. Although there are no complaints that this vaccine has caused side effects in India, there is an expectation as to when it will be released as Phase 3 data is important.